Daniel T Chang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8502608/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pancreatic Stereotactic Body Radiation Therapy With or Without Hypofractionated Elective Nodal Irradiation. International Journal of Radiation Oncology Biology Physics, 2022, 112, 131-142.	0.8	26
2	Progression versus Radiation Treatment Changes after Stereotactic Ablative Radiotherapy of a Liver Metastasis Practical Radiation Oncology, 2022, 12, 1-2.	2.1	0
3	Automated model versus treating physician for predicting survival time of patients with metastatic cancer. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1108-1116.	4.4	23
4	Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2021, 11, 13-25.	2.1	67
5	Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 1069-1081.	7.0	75
6	Development and validation of a model to predict survival in colorectal cancer using a gradient-boosted machine. Gut, 2021, 70, 884-889.	12.1	30
7	Longitudinal Analysis of Mental Disorder Burden Among Elderly Patients With Gastrointestinal Malignancies. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 163-171.	4.9	3
8	Impact of mental illness on endâ€ofâ€life emergency department use in elderly patients with gastrointestinal malignancies. Cancer Medicine, 2021, 10, 2035-2044.	2.8	5
9	Predicting treatment response from longitudinal images using multi-task deep learning. Nature Communications, 2021, 12, 1851.	12.8	87
10	Liver Metastasis–Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients. Pancreas, 2021, 50, 736-743.	1.1	7
11	Trimodality Versus Bimodality Therapy in Patients With Locally Advanced Esophageal Carcinoma: Commentary on the American Society of Clinical Oncology Practice Guidelines. Practical Radiation Oncology, 2021, 11, 429-433.	2.1	2
12	Local Recurrence Outcomes of Colorectal Cancer Oligometastases Treated With Stereotactic Ablative Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 559-564.	1.3	6
13	Can Sex and Seniority Predict the Quality of a Journal Reviewer's Manuscript Critique?. International Journal of Radiation Oncology Biology Physics, 2021, 111, 312-316.	0.8	2
14	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 541-565.	4.9	477
15	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2021, 39, 3773-3777.	1.6	17
16	First Beam Commissioning Report of a Novel Medical Linear Accelerator Designed for Biologically Guided Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2021, 111, e512.	0.8	0
17	Rectosigmoid Cancer $\hat{a} \in$ Rectal Cancer or Sigmoid Cancer?. International Journal of Radiation Oncology Biology Physics, 2021, 111, e47.	0.8	0
18	Analysis of Pathologic Complete Response Rates Between Different Neoadjuvant Radiation Treatment Regimens for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 111, e52.	0.8	0

#	Article	IF	CITATIONS
19	Reflections on Anthony Zietman From Gastrointestinal Cancer and Physics Editors. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1114-1117.	0.8	0
20	Automated hepatobiliary toxicity prediction after liver stereotactic body radiation therapy with deep learning-based portal vein segmentation. Neurocomputing, 2020, 392, 181-188.	5.9	6
21	Survival after neoadjuvant approaches to gastroesophageal junction cancer. Gastric Cancer, 2020, 23, 175-183.	5.3	12
22	Stereotactic Body Radiation Therapy for Cholangiocarcinoma: Optimizing Locoregional Control With Elective Nodal Irradiation. Advances in Radiation Oncology, 2020, 5, 77-84.	1.2	20
23	Predicting Survival for Patients With Metastatic Disease. International Journal of Radiation Oncology Biology Physics, 2020, 106, 52-60.	0.8	18
24	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). Practical Radiation Oncology, 2020, 10, e136-e146.	2.1	41
25	The clinical and financial cost of mental disorders among elderly patients with gastrointestinal malignancies. Cancer Medicine, 2020, 9, 8912-8922.	2.8	4
26	Signet ring cell carcinoma of the Ampulla of Vater: outcomes of patients in the United States. Hpb, 2020, 22, 1759-1765.	0.3	7
27	Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Radiotherapy and Oncology, 2020, 152, 63-69.	0.6	19
28	Telemedicine in Radiation Oncology: Is It Here to Stay? Impacts on Patient Care and Resident Education. International Journal of Radiation Oncology Biology Physics, 2020, 108, 416-420.	0.8	18
29	Virtual Radiation Oncology Clerkship During the COVID-19 Pandemic and Beyond. International Journal of Radiation Oncology Biology Physics, 2020, 108, 444-451.	0.8	20
30	Importance of a Culture Committee for Boosting Morale and Maintaining a Healthy Work Environment in Radiation Oncology. Advances in Radiation Oncology, 2020, 5, 1115-1117.	1.2	3
31	Second cancer risk after primary cancer treatment with threeâ€dimensional conformal, intensityâ€modulated, or proton beam radiation therapy. Cancer, 2020, 126, 3560-3568.	4.1	105
32	Abdominal and Pelvic Reirradiation for Recurrent Gastrointestinal Cancers. Seminars in Radiation Oncology, 2020, 30, 232-237.	2.2	1
33	Deep learning for identification of critical regions associated with toxicities after liver stereotactic body radiation therapy. Medical Physics, 2020, 47, 3721-3731.	3.0	22
34	Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1586-1595.	2.5	8
35	Continuing Medical Student Education During the Coronavirus Disease 2019 (COVID-19) Pandemic: Development of a Virtual Radiation Oncology Clerkship. Advances in Radiation Oncology, 2020, 5, 732-736.	1.2	36
36	The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma. Practical Radiation Oncology, 2020, 10, 274-281.	2.1	8

#	Article	IF	CITATIONS
37	Outcomes and Tolerability of Definitive and Preoperative Chemoradiation in Elderly Patients With Esophageal Cancer: A Retrospective Institutional Review. Advances in Radiation Oncology, 2020, 5, 1188-1196.	1.2	6
38	Cost-Effectiveness and Quality-Adjusted Survival of Watch and Wait After Complete Response to Chemoradiotherapy for Rectal Cancer. Journal of the National Cancer Institute, 2020, 112, 792-801.	6.3	23
39	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell, 2020, 181, 832-847.e18.	28.9	77
40	Treating Oligometastatic Disease With SABR: More Than Just a Numbers Game?. International Journal of Radiation Oncology Biology Physics, 2020, 107, 257-260.	0.8	8
41	Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database. Radiotherapy and Oncology, 2020, 143, 101-107.	0.6	18
42	Local control and toxicity outcomes of stereotactic radiosurgery for spinal metastases of gastrointestinal origin. Journal of Neurosurgery: Spine, 2020, 33, 87-94.	1.7	11
43	Abstract PR-006: Spatially resolved, single cell assessment of pancreatic ductal adenocarcinoma expression subtypes reveals mixed and hybrid basal-classical marker expression with prognostic significance and discrete spatial localization. , 2020, , .		1
44	Abstract PO-013: MTAP protein expression is lost in nearly one-third of primary pancreatic cancers and is associated with sensitivity to MAT2A inhibition in patient-derived organoid models. , 2020, , .		0
45	Abstract PR-001: Neoadjuvant therapy is associated with altered composition of immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer. , 2020, , .		0
46	Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genetics in Medicine, 2019, 21, 213-223.	2.4	151
47	The Burden of Mental Health Disorders Among Elderly Patients with Gastrointestinal Malignancies. International Journal of Radiation Oncology Biology Physics, 2019, 103, E30-E31.	0.8	1
48	Markerless Pancreatic Tumor Target Localization Enabled By Deep Learning. International Journal of Radiation Oncology Biology Physics, 2019, 105, 432-439.	0.8	49
49	Impact of Accuracy of Survival Predictions on Quality of End-of-Life Care Among Patients With Metastatic Cancer Who Receive Radiation Therapy. Journal of Oncology Practice, 2019, 15, e262-e270.	2.5	22
50	Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer. Journal of Gastrointestinal Oncology, 2019, 10, 605-615.	1.4	4
51	Clinical and Economic Impact of Mental Health Illnesses Surrounding a Gastrointestinal Malignancy Among Elderly Patients. International Journal of Radiation Oncology Biology Physics, 2019, 105, E595-E596.	0.8	0
52	Prognostic Model Using a Simple Survival Tree Algorithm for Patients Undergoing Palliative Radiation. International Journal of Radiation Oncology Biology Physics, 2019, 105, E581.	0.8	1
53	Stereotactic Body Radiotherapy for Cholangiocarcinoma: Optimizing Locoregional Control with Elective Nodal Irradiation. International Journal of Radiation Oncology Biology Physics, 2019, 105, E223-E224.	0.8	0
54	Improved Survival with Modified Folfirinox and Higher Doses of Stereotactic Body Radiation Therapy for Treatment of Locally Advanced Pancreatic Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, E232-E233.	0.8	0

#	Article	lF	CITATIONS
55	Tolerability and Toxicity of Definitive and Preoperative Chemoradiation in Octogenarian Patients with Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, E196.	0.8	0
56	Deep Learning Approach for Markerless Pancreatic Tumor Target Localization. International Journal of Radiation Oncology Biology Physics, 2019, 105, S202-S203.	0.8	2
57	Neural Networks for Deep Radiotherapy Dose Analysis and Prediction of Liver SBRT Outcomes. IEEE Journal of Biomedical and Health Informatics, 2019, 23, 1821-1833.	6.3	25
58	SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer. Modern Pathology, 2019, 32, 1217-1231.	5.5	35
59	Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System. Pancreas, 2019, 48, 622-628.	1.1	12
60	Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 573-580.	1.3	26
61	Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data. Journal of the National Cancer Institute, 2019, 111, 568-574.	6.3	34
62	Abstract A35: Microenvironmental adaptations drive obesity-associated pancreatic cancer. , 2019, , .		0
63	Strategies for prediction and mitigation of radiation-induced liver toxicity. Journal of Radiation Research, 2018, 59, i40-i49.	1.6	33
64	Resectable and Borderline Resectable Pancreatic Cancer. Practical Guides in Radiation Oncology, 2018, , 199-229.	0.1	0
65	Management of Borderline Resectable Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1155-1174.	0.8	48
66	Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 242-247.	1.3	54
67	Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncology, 2018, 4, e173420.	7.1	155
68	Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 486-489.	0.8	2
69	Worsening of Child-Pugh Score after Stereotactic Body Radiation Therapy Significantly Impacts Survival of Patients Treated for Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, e64.	0.8	1
70	Comparing Modalities Using the National Cancer Database: Concerns With Rajyaguru et al. Journal of Clinical Oncology, 2018, 36, 2557-2557.	1.6	1
71	Validation of a RPA prognostic model to predict overall survival in patients treated with bone metastases. International Journal of Radiation Oncology Biology Physics, 2018, 102, e440.	0.8	1
72	Quality of End of Life Care among Metastatic Cancer Patients Receiving Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, e423.	0.8	0

#	Article	IF	CITATIONS
73	Predicting Survival after Liver SBRT by Deep Learning-Based Analysis of Treatment Dose Plans. International Journal of Radiation Oncology Biology Physics, 2018, 102, e56.	0.8	1
74	Sarcopenia in Overweight or Obese Patient is an Adverse Prognostic Factor in Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e76.	0.8	2
75	Introduction. Seminars in Radiation Oncology, 2018, 28, 265-266.	2.2	Ο
76	Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Seminars in Radiation Oncology, 2018, 28, 295-308.	2.2	4
77	Probabilistic Prognostic Estimates of Survival in Metastatic Cancer Patients (PPES-Met) Utilizing Free-Text Clinical Narratives. Scientific Reports, 2018, 8, 10037.	3.3	18
78	The role of bone marrow and spleen irradiation in the development of acute hematologic toxicity during chemoradiation for esophageal cancer. Advances in Radiation Oncology, 2018, 3, 297-304.	1.2	12
79	Development of deep neural network for individualized hepatobiliary toxicity prediction after liver <scp>SBRT</scp> . Medical Physics, 2018, 45, 4763-4774.	3.0	103
80	Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity. Advances in Radiation Oncology, 2018, 3, 621-629.	1.2	38
81	Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation. American Journal of Surgical Pathology, 2018, 42, 1409-1417.	3.7	24
82	The Prognostic Significance of Pretreatment Hematologic Parameters in Patients Undergoing Resection for Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 405-412.	1.3	46
83	Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. Practical Radiation Oncology, 2017, 7, 173-182.	2.1	42
84	Pancreatic, Rectal, and Liver Cancers: Out With the Old, In With the New. International Journal of Radiation Oncology Biology Physics, 2017, 97, 643-650.	0.8	0
85	The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 177-185.	0.8	24
86	Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET. Practical Radiation Oncology, 2017, 7, 120-125.	2.1	6
87	Does radiotherapy still have a role in unresected biliary tract cancer?. Cancer Medicine, 2017, 6, 129-141.	2.8	32
88	Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 99, 417-426.	0.8	67
89	Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma. Advances in Radiation Oncology, 2017, 2, 27-36.	1.2	21
90	Normal Tissue Constraints for Abdominal and Thoracic Stereotactic Body Radiotherapy. Seminars in Radiation Oncology, 2017, 27, 197-208.	2.2	68

6

#	Article	IF	CITATIONS
91	Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. Radiology, 2017, 283, 460-468.	7.3	36
92	Perfusion CT measurements predict tumor response in rectal carcinoma. Abdominal Radiology, 2017, 42, 1132-1140.	2.1	11
93	Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. British Journal of Cancer, 2017, 117, 1874-1882.	6.4	73
94	Outcomes and Characteristics of Patients Treated with Emergent Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, S221-S222.	0.8	0
95	A Pilot Curriculum for Transitioning Radiation Oncology Residents. International Journal of Radiation Oncology Biology Physics, 2017, 99, E125.	0.8	0
96	A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Cancer Cell, 2017, 32, 460-473.e6.	16.8	142
97	(P089) Comparison of Survival by Different Palliative Radiation Therapy Fractionation Schedules. International Journal of Radiation Oncology Biology Physics, 2017, 98, E39.	0.8	0
98	Radiation Therapy for Hepatocellular Carcinoma: Clinical Data. , 2017, , 179-198.		0
99	Radiation Therapy for Colorectal Liver Metastases. Current Colorectal Cancer Reports, 2017, 13, 240-249.	0.5	1
100	Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma. Neuro-Oncology, 2017, 19, 1651-1660.	1.2	15
101	Central liver toxicity after SBRT: An expanded analysis and predictive nomogram. Radiotherapy and Oncology, 2017, 122, 130-136.	0.6	71
102	Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. International Journal of Radiation Oncology Biology Physics, 2017, 97, 306-312.	0.8	27
103	Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma. Journal of Oncology Practice, 2017, 13, e992-e1001.	2.5	8
104	Nonoperative Management of Rectal Cancer: A Modern Perspective. Oncology, 2017, 31, e13-e22.	0.5	2
105	Dosimetric analysis of isocentrically shielded volumetric modulated arc therapy for locally recurrent nasopharyngeal cancer. Scientific Reports, 2016, 6, 25959.	3.3	0
106	Robotic intrafractional US guidance for liver SABR: System design, beam avoidance, and clinical imaging. Medical Physics, 2016, 43, 5951-5963.	3.0	17
107	Quantitative Analysis of 18F-Fluorodeoxyglucose Positron Emission Tomography Identifies Novel Prognostic Imaging Biomarkers in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016 96 102-109	0.8	44
108	Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. Practical Radiation Oncology, 2016, 6, 417-424.	2.1	19

#	Article	IF	CITATIONS
109	Effectiveness of Radiation Therapy for Low- to Intermediate-Grade Neuroendocrine Tumors. International Journal of Radiation Oncology Biology Physics, 2016, 96, E202-E203.	0.8	1
110	Hematologic Toxicity During Anal Cancer Treatment: The Importance of Pelvic Bone Marrow Volume and Limiting Radiation Dose to a Critical Marrow Volume. International Journal of Radiation Oncology Biology Physics, 2016, 96, E216.	0.8	1
111	Radiation Therapy Fractionation Practice Patterns in End-of-Life Care. International Journal of Radiation Oncology Biology Physics, 2016, 96, E508-E509.	0.8	0
112	Fractionation of Palliative Radiation Therapy in Metastatic Breast Cancer—Selection and Survival. International Journal of Radiation Oncology Biology Physics, 2016, 96, E513.	0.8	0
113	Multicohort Analysis of Effect of Ionizing Radiation on Transcription Identifies Conserved Gene Signature and Clinically Relevant Novel Radiosensitizers. International Journal of Radiation Oncology Biology Physics, 2016, 96, E590.	0.8	0
114	Multiplex Proximal Ligation Assay Identifies Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, E597-E598.	0.8	0
115	Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2016, 34, 902-909.	1.6	99
116	A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. PLoS ONE, 2016, 11, e0147995.	2.5	13
117	Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: a phase II study. Oncotarget, 2016, 7, 22711-22719.	1.8	32
118	How Common is Stress and Burnout Among Residency Program Directors in United States Radiation Oncology Programs?. International Journal of Radiation Oncology Biology Physics, 2015, 93, E374.	0.8	1
119	Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 911-920.	0.8	112
120	Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 568-576.	0.8	75
121	Phase 2 multiâ€institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer, 2015, 121, 1128-1137.	4.1	447
122	Predictors of Toxicity Associated With Stereotactic Body Radiation Therapy toÂtheÂCentral Hepatobiliary Tract. International Journal of Radiation Oncology Biology Physics, 2015, 91, 986-994.	0.8	65
123	Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer. Journal of Clinical Pathology, 2015, 68, 341-345.	2.0	37
124	Survival benefit for adjuvant radiation therapy in minor salivary gland cancers. Oral Oncology, 2015, 51, 438-445.	1.5	20
125	Stress and Burnout Among Residency ProgramÂDirectors in United States Radiation Oncology Programs. International Journal of Radiation Oncology Biology Physics, 2015, 93, 746-753.	0.8	24
126	Serum Transforming Growth Factor-Î ² 1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1023-1031.	0.8	2

#	Article	IF	CITATIONS
127	Multiplex proximity ligation assay to identify a biomarker panel for prognosis in unresectable pancreatic cancer patients treated with stereotactic body radiation therapy. International Journal of Radiation Oncology Biology Physics, 2015, , .	0.8	0
128	Radiomic Analysis of FDG-PET Identifies Novel Prognostic Imaging Biomarkers in Locally Advanced Pancreatic Cancer Patients Treated With SBRT. International Journal of Radiation Oncology Biology Physics, 2015, 93, S4-S5.	0.8	1
129	Posttreatment PET-CT is Predictive of Local Control After Liver Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, E181.	0.8	0
130	Dosimetric Predictors of Surgical Complications From Esophagectomy After Neoadjuvant Chemoradiation for Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, E131.	0.8	4
131	Stereotactic Body Radiation for Pancreatic Cancer: Results of an International Survey of Practice Patterns. International Journal of Radiation Oncology Biology Physics, 2015, 93, E132.	0.8	3
132	Stereotactic body radiation therapy and central liver toxicity: A case report. Practical Radiation Oncology, 2015, 5, 282-285.	2.1	11
133	Stereotactic body radiation therapy in pancreatic cancer: the new frontier. Expert Review of Anticancer Therapy, 2014, 14, 1461-1475.	2.4	31
134	Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma. Pancreas, 2014, 43, 777-783.	1.1	1
135	Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes inÂPatients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 539-546.	0.8	70
136	Radiotherapy for adenoid cystic carcinomas of the head and neck: clinical outcomes and patterns of failure. Journal of Radiation Oncology, 2014, 3, 49-56.	0.7	2
137	Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal. Practical Radiation Oncology, 2014, 4, 198-206.	2.1	31
138	Stereotactic Body Radiotherapy in the Treatment of Pancreatic Cancer. Seminars in Radiation Oncology, 2014, 24, 140-147.	2.2	50
139	Serum Vascular Endothelial Growth Factor-A and Transforming Growth Factor-Î ² 1 Can Predict Pathological Response and Disease-Free Survival of Esophageal Cancer Patients Treated with Neoadjuvant Chemoradiation Therapy Followed by Esophagectomy. International Journal of Radiation Oncology Biology Physics, 2014, 90, S9-S10.	0.8	5
140	Pooled Analysis of Liver Stereotactic Body Radiation Therapy for Colorectal Metastases: Results From 5 Institutions. International Journal of Radiation Oncology Biology Physics, 2014, 90, S376.	0.8	1
141	Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity. International Journal of Radiation Oncology Biology Physics, 2014, 90, 918-925.	0.8	98
142	Lower Pelvis Bone Marrow Dose Constraints to Reduce Hematologic Toxicity in the Treatment of Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S33.	0.8	3
143	High Serum Levels of Vascular Endothelial Growth Factor-A and Transforming Growth Factor-Î ² 1 Before Neoadjuvant Chemoradiotherapy Predict Poor Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Combined Modality Therapy. Annals of Surgical Oncology, 2014, 21. 2361-2368.	1.5	21
144	False positive 18F-fluorodeoxyglucose positron emission tomography/computed tomography liver lesion mimicking metastasis in 2 patients with gastroesophageal cancer. Practical Radiation Oncology, 2014, 4, 368-371.	2.1	2

#	Article	IF	CITATIONS
145	In Reply to Leung. International Journal of Radiation Oncology Biology Physics, 2014, 88, 241-242.	0.8	Ο
146	Penile metastases originating from a pancreatic primary tumor: a case report. Journal of Radiation Oncology, 2013, 2, 107-112.	0.7	0
147	A Phase 2 Multicenter Study to Evaluate Gemcitabine and Fractionated Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2013, 87, S28.	0.8	6
148	Generation of Consensus Contour Atlas for Esophageal Cancer IMRT. International Journal of Radiation Oncology Biology Physics, 2013, 87, S293.	0.8	0
149	The role of adjuvant chemoradiation in the treatment of pancreatic cancer. Journal of Radiation Oncology, 2013, 2, 391-400.	0.7	Ο
150	Dosimetric Analysis of Organs at Risk During Expiratory Gating in Stereotactic Body Radiation Therapy for Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1090-1095.	0.8	50
151	Safety of 90Y Radioembolization in Patients Who Have Undergone Previous External Beam Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, 323-329.	0.8	38
152	SMAD4 Inactivation and Prognosis in Colorectal Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, S342.	0.8	0
153	Clinical and Dosimetric Predictors of Perioperative Pulmonary Complications in Esophageal Cancer Patients Treated With Neoadjuvant Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2013, 87, S300-S301.	0.8	0
154	Factors that Determine Academic Versus Private Practice Career Interest in Radiation Oncology Residents in the United States: Results of a Nationwide Survey. International Journal of Radiation Oncology Biology Physics, 2013, 87, 464-470.	0.8	14
155	18Flurodeoxyglucose-PET Baseline Avidity Predicts for Inferior Outcomes in Patients With Locally-Advanced Pancreatic Cancer Treated With Gemcitabine and Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, S308-S309.	0.8	1
156	Metabolic Tumor Volume Predicts Disease Progression and Survival in Patients with Squamous Cell Carcinoma of the Anal Canal. Journal of Nuclear Medicine, 2013, 54, 27-32.	5.0	51
157	Patterns of Care in Palliative Radiotherapy: A Population-Based Study. Journal of Oncology Practice, 2013, 9, e220-e227.	2.5	93
158	Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy. OncoTargets and Therapy, 2013, 6, 1097.	2.0	2
159	Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. Journal of Gastrointestinal Oncology, 2013, 4, 343-51.	1.4	55
160	BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon. American Journal of Surgical Pathology, 2012, 36, 744-752.	3.7	161
161	Orthovoltage Intraoperative Radiotherapy for Locally Advanced and Recurrent Colorectal Cancer. Diseases of the Colon and Rectum, 2012, 55, 695-702.	1.3	12
162	Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, e595-e601.	0.8	34

#	Article	IF	CITATIONS
163	Postchemoradiotherapy Positron Emission Tomography Predicts Pathologic Response and Survival in Patients With Esophageal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, 471-477.	0.8	54
164	Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity in Patients Treated With Intensity-Modulated Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. International Journal of Radiation Oncology Biology Physics, 2012, 84, 700-706.	0.8	81
165	Intrafraction Verification of Gated RapidArc by Using Beam-Level Kilovoltage X-Ray Images. International Journal of Radiation Oncology Biology Physics, 2012, 83, e709-e715.	0.8	27
166	Modern Radiation Therapy Techniques for Pancreatic Cancer. Gastroenterology Clinics of North America, 2012, 41, 223-235.	2.2	9
167	Evaluation of a metal artifact reduction technique in tonsillar cancer delineation. Practical Radiation Oncology, 2012, 2, 27-34.	2.1	9
168	Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Modern Pathology, 2012, 25, 1128-1139.	5.5	250
169	Reduced Toxicity in Inflammatory Bowel Disease Patients Treated With Intensity Modulated Radiation Therapy (IMRT). International Journal of Radiation Oncology Biology Physics, 2012, 84, S355.	0.8	0
170	Combined Modality Therapy for Rectal Cancer: The Relative Value of Posttreatment Versus Pretreatment CEA as a Prognostic Marker for Disease Recurrence. Annals of Surgical Oncology, 2012, 19, 2471-2476.	1.5	22
171	Costâ€effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer, 2012, 118, 1119-1129.	4.1	55
172	WE-A-BRA-04: Real-Time Telerobotic 3D Ultrasound for Soft-Tissue Guidance Concurrent with Beam Delivery. Medical Physics, 2012, 39, 3934-3935.	3.0	0
173	Commentary: How radiation damages teeth: Getting to the root of the problem. Practical Radiation Oncology, 2011, 1, 149-151.	2.1	1
174	Rectal and bladder deformation and displacement during preoperative radiotherapy for rectal cancer: Are current margin guidelines adequate for conformal therapy?. Practical Radiation Oncology, 2011, 1, 85-94.	2.1	19
175	Intrafraction Verification using Beam Level kV Images for Gated RapidArc. International Journal of Radiation Oncology Biology Physics, 2011, 81, S152-S153.	0.8	0
176	Pattern of Lymph Node Involvement and Prognosis in Pancreatic Adenocarcinoma. American Journal of Surgical Pathology, 2011, 35, 228-234.	3.7	36
177	Intensityâ€modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer, 2011, 117, 3342-3351.	4.1	132
178	Stereotactic body radiotherapy for colorectal liver metastases. Cancer, 2011, 117, 4060-4069.	4.1	265
179	Prospective Randomized Double-Blind Pilot Study of Site-Specific Consensus Atlas Implementation for Rectal Cancer Target Volume Delineation in the Cooperative Group Setting. International Journal of Radiation Oncology Biology Physics, 2011, 79, 481-489.	0.8	79
180	Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell Carcinoma: Patterns of Failure and Predictors of Local Control. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1412-1422.	0.8	63

#	Article	IF	CITATIONS
181	Single-Fraction Stereotactic Body Radiation Therapy and Sequential Gemcitabine for the Treatment of Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 181-188.	0.8	230
182	A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male. Rare Tumors, 2011, 3, 141-145.	0.6	12
183	Stereotactic Body Radiation Therapy for Gastrointestinal Malignancies. Frontiers of Radiation Therapy and Oncology, 2011, 43, 412-427.	1.4	15
184	Interfractional Uncertainty in the Treatment of Pancreatic Cancer With Radiation. International Journal of Radiation Oncology Biology Physics, 2010, 76, 603-607.	0.8	59
185	A Dosimetric Model of Duodenal Toxicity After Stereotactic Body Radiotherapy for Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1420-1426.	0.8	143
186	Expression of p16 ^{INK4A} but not hypoxia markers or poly adenosine diphosphateâ€ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Cancer, 2010, 116, 5179-5187.	4.1	16
187	Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: Clinical Outcomes and Patterns of Failure. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1339-1346.	0.8	110
188	18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1420-1425.	0.8	119
189	Rectal Deformation and Displacement during Pre-operative Radiotherapy for Rectal Cancer: Insights from Mid-treatment Cone-beam Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2010, 78, S310.	0.8	Ο
190	Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma. Radiation Oncology, 2010, 5, 105.	2.7	7
191	EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy. Gastrointestinal Endoscopy, 2010, 71, 513-518.	1.0	148
192	Management of T1/T2 Rectal Cancers with Transanal Excision and Radiation Therapy. Radiation Medicine Rounds, 2010, 1, 323-333.	0.0	0
193	Percutaneous Implantation of Fiducial Markers for Imaging-Guided Radiation Therapy. American Journal of Roentgenology, 2009, 192, 1090-1096.	2.2	43
194	Pharmacologically Increased Tumor Hypoxia Can Be Measured by 18F-Fluoroazomycin Arabinoside Positron Emission Tomography and Enhances Tumor Response to Hypoxic Cytotoxin PR-104. Clinical Cancer Research, 2009, 15, 7170-7174.	7.0	31
195	Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer, 2009, 115, 665-672.	4.1	353
196	Duodenal Toxicity in Single-fraction Stereotactic Body Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, S29-S30.	0.8	3
197	Comparison of IMRT and 3D Conformal Radiotherapy for Adjuvant Therapy for Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, S259.	0.8	2
198	Intensity Modulated Radiotherapy for Adenocarcinoma of the Pancreas. International Journal of Radiation Oncology Biology Physics, 2009, 75, S272-S273.	0.8	0

#	Article	IF	CITATIONS
199	Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. Journal of Translational Medicine, 2009, 7, 105.	4.4	50
200	Long-term Outcomes for Stage l–II Aggressive Non-Hodgkin Lymphoma of Waldeyer's Ring. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 233-237.	1.3	13
201	Xerostomia in Long-term Survivors of Aggressive Non-Hodgkin's Lymphoma of Waldeyer's Ring. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 145-149.	1.3	12
202	Pancreatic Tumor Motion on a Single Planning 4D-CT Does Not Correlate With Intrafraction Tumor Motion During Treatment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 364-368.	1.3	92
203	Intensity Modulated Radiotherapy for Squamous Cell Carcinoma of the Hypopharynx and Larynx: Clinical Outcomes and Patterns of Failure. International Journal of Radiation Oncology Biology Physics, 2008, 72, S405-S406.	0.8	0
204	Positron Emission Tomography for Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, S268-S269.	0.8	0
205	Predicting Changes in Dose Distribution to Tumor and Normal Tissue When Correcting for Heterogeneity in Radiotherapy for Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 57-62.	1.3	11
206	Do pre-irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible?. Head and Neck, 2007, 29, 528-536.	2.0	121
207	Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy: The importance of radiation field selection. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1043-1051.	0.8	17
208	The impact of heterogeneity correction on dosimetric parameters that predict for radiation pneumonitis. International Journal of Radiation Oncology Biology Physics, 2006, 65, 125-131.	0.8	28
209	Adjuvant radiotherapy for cutaneous melanoma: Comparing hypofractionation to conventional fractionation. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1051-1055.	0.8	97
210	Re-Examining the Role of Elective Nodal Irradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 597-602.	1.3	10
211	Merkel cell carcinoma of the skin with leptomeningeal metastases. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2005, 26, 210-213.	1.3	18